Most chronic renal failure patients with severe refractory hyperparathyroidism harbor at least one monoclonal parathyroid tumor, but the specific acquired genetic defects that confer this clonal selective advantage remain poorly understood. Somatic inactivation of the vitamin D receptor (VDR) gene could contribute to clonal outgrowth, because a parathyroid cell containing this lesion would have an impaired response to the antiproliferative influence of 1,25-dihydroxyvitamin D 3 . Furthermore, diminished expression of VDR protein has been described in uremia-associated parathyroid tumors. Therefore, to assess VDR gene inactivation's potential pathogenetic role in this disease, we rigorously analyzed the VDR gene in 59 parathyroid tumors surgically resected from uremic patients.
First, Southern blotting and/or PCR analyses of 29 tumor samples from 14 genetically informative patients revealed no allelic losses at the VDR locus. Next, direct DNA sequencing of all VDR splice junctions, associated intronic sequences, and virtually the entire VDRcoding region for all 59 tumors revealed no acquired mutations. Last, 37 tumor DNA samples were subjected to comparative genomic hybridization, and no chromosomal losses in the VDR region (12cen-q12) were observed.
These observations suggest that inactivating defects within the VDR gene do not commonly contribute to the primary pathogenesis of severe refractory hyperparathyroidism in uremia. (J Clin Endocrinol Metab 85: 868 -872, 2000) P ARATHYROID CELL growth in the setting of chronic renal failure is initially polyclonal and later can become monoclonal. Monoclonal parathyroid growths are common in hemodialysis patients who become refractory to standard medical therapy for secondary hyperparathyroidism and who therefore require parathyroidectomy (1, 2) . Thus, the development of monoclonal neoplasia may be a key contributor to this state of apparent parathyroid gland autonomy. Several factors are thought to contribute to the early polyclonal expansion of parathyroid cells, including abnormal vitamin D metabolism, hypocalcemia, and hyperphosphatemia. Factors contributing to the monoclonal expansion of parathyroid cells in the context of severe uremia, however, are largely unknown.
The existence of a monoclonal tumor implies that acquired (somatic) mutation in genes controlling cell proliferation or programmed cell death must have conferred a selective growth advantage on a parathyroid cell sufficient to lead to its clonal expansion (3) . Although defects in two such genes, cyclinD1/PRAD1 and MEN1, are found in subsets of common parathyroid adenomas (4 -8) , specific oncogenes or tumor suppressor genes contributing to monoclonal uremic hyperparathyroidism have not yet been identified.
The vitamin D system represents an attractive potential target for acquired genetic mutation in parathyroid cells of uremic patients because of calcitriol's effects on parathyroid cell growth and function. Calcitriol acts via its nuclear receptor to suppress parathyroid cell growth and downregulate PTH synthesis and secretion (9) . Vitamin D and its receptor may also play a role in determining the set-point of calcium-regulated PTH secretion, which has been shown to be abnormal in severe uremic hyperparathyroidism (10) . Thus, an acquired mutation that inactivates the function of the vitamin D receptor (VDR) could confer a proliferative advantage on a parathyroid cell. Furthermore, although decreased VDR density has been observed in the parathyroid glands of both rats and dogs with experimental uremia and in patients with severe uremic hyperparathyroidism (11) (12) (13) (14) (15) , the finding of recurrent clonal defects in the VDR gene would provide solid evidence that such abnormalities in VDR expression are truly a primary contributing cause of the proliferative disturbance. Therefore, to assess the potential role of the VDR in the pathogenesis of monoclonal parathyroid tumors in chronic renal failure, we evaluated 59 surgically resected parathyroid tumors from uremic patients for acquired inactivating mutations in the vitamin D receptor gene.
Subjects and Methods

Patients and tumor samples
Parathyroid tumor tissue and paired normal peripheral blood leukocytes were obtained from 33 patients (15 men and 18 women) with an average age of 43.5 yr (range, 19 -63 yr) who underwent surgical treatment for refractory uremic hyperparathyroidism. Indications for parathyroidectomy included intractable pruritus, bone pain and/or fractures, soft tissue calcifications, hypercalcemia, marked hyperphosphatemia, x-ray signs of renal osteodystrophy, and/or other symptoms that could not be controlled with medical therapy. Serum calcium levels were available for 32 of 33 patients. Nineteen of these 32 were normocalcemic; 13 were hypercalcemic, with an average total serum calcium of 11.5 mg/dL (range, 10.6 -13 mg/dL), and were considered to have tertiary hyperparathyroidism. Serum PTH levels were elevated in all patients from whom data were available (32 of 33) to an average 16-fold above the upper limit of normal (range, 3.8-to 35-fold). The number of years on intermittent dialysis treatment ranged from 0.5-18, with an average of 10 yr (data available from 30 of 33 patients, 2 patients were on continuous ambulatory peritoneal dialysis, the remaining 28 were on hemodialysis). A single hypercellular parathyroid gland was available for study from 16 patients, 2 glands were available from each of 11 patients, 3 glands were available from each of 3 patients, 4 glands were available from each of 2 patients, and from 1 patient parathyroid tissue was taken from an enlarged forearm autograft. In total, 59 parathyroid samples were obtained. Seventeen tumors were classified as nodular hyperplasia, and 32 were classified as generalized hyperplasia (9 tumors were not categorized or data were unavailable). The mean gland weight (data available for 24 of 59 tumor samples) was 1177 mg (range, 20 -5980 mg). All tumors were snap-frozen immediately after surgical resection and stored at Ϫ80 C. Genomic DNA was isolated from tumor and peripheral blood leukocytes using standard techniques of proteinase K digestion and phenol/chloroform extraction. All samples were obtained in accordance with the regulations of the institutional review board on human studies.
Analysis of allelic loss at the VDR locus
Restriction digestion of paired peripheral blood leukocytes and tumor genomic DNA was performed with TaqI and subjected to Southern blotting using the 2.1-kb EcoRI fragment of human VDR complementary DNA plasmid pH13 as a probe (American Type Culture Collection, Manassas, VA). The presence of the polymorphic TaqI site in codon 352 yields a band of 2.0 kb (and invariant bands of 12.2, 10.2, and 1.5 kb) on the autoradiogram, whereas the absence of the polymorphic site yields a 2.2-kb band (16) . For PCR analysis of allelic loss, exon 9 of the VDR gene was PCR amplified as described by Morrison et al. (17) , and a TaqI restriction digest was performed. Products were separated on agarose gel containing ethidium bromide and visualized under UV light. Samples homozygous for the presence of the polymorphic site (tt) yield bands of 290, 245 (invariant), and 205 bp, whereas samples homozygous for the absence of the polymorphic site (TT) yield bands of 495 and 245 bp (18) . The heterozygous (Tt) pattern thus contains bands of 495, 290, 245, and 205 bp. Relative allele intensities were assessed to determine whether one VDR allele was selectively lost in the patient's tumor DNA.
Direct DNA sequencing
All eight coding exons were PCR amplified using the following intronic primers, based upon the VDR gene organization (19) and genomic sequence obtained by one of us (J.W.P.): exon 2: 2F, 5Ј-AGGAAT-TCAGCTGGCCCTGGCACTGACTCTGCTCT-3Ј; 2R, 5Ј-CTGAATTCA-TGGAAACACCTTGCTTCTTCTCCCTC-3Ј; exon 3: 3F, 5Ј-GTGAAT-TCAGGGTGAGGAGCCGGAAGTTCAGTGAC-3Ј; 3R, 5Ј-GCGAATTC-CTTTCCCTGACTCCACTTCAGGCCCAA-3Ј; exons 4 and 5 (amplified and sequenced together): 4/5F, 5Ј-GAGAATTCTGAGAGCTGCTG-CAGC-3Ј; 4/5Fa, 5Ј-CATTCTGACAGATGAGGAAGTGC-3Ј; 4/5R, 5Ј-CCGAATTCTATGGAGACTGAAGTCCTG-3Ј; exon 6: 6F, 5Ј-TGGAAT-TCCAGTCTGGCTCTGCTG-3Ј;6R,5Ј-TTGAATTCTTGTAGCTCAGTC-TAGGA-3Ј; exons 7 and 8 (amplified and sequenced together): 7/8F, 5Ј-GCGAATTCCGTTACTGGTAACCTGACCTCCTTC-3Ј; 7/8R, 5Ј-AATTCATACACCCCGCTCCCCACGTCCCTGAG-3Ј; and exon 9: 9F, 5Ј-TGGAATTCAGCAGTGAGGTGCCCAGCTGAG-3Ј; 9R, 5Ј-TCGA-ATTCTGAGGAGGGCTGCTGAGTAGCC-3Ј.
Cycle sequencing reactions were performed on column-purified PCR product using each of the above primers and Big Dye fluorescencelabeled deoxy-NTPs (PE Applied Biosystems, Foster City, CA). Each exon was sequenced in both the forward and reverse directions. Products were separated on a denaturing polyacrylamide/formamide gel and visualized using the ABI Prism 377 DNA Sequencer (PE Applied Biosystems, Foster City, CA).
In total, over 98% of the VDR-coding region was successfully amplified and sequenced. PCR amplification of exons 4 and 5 with the intronic primers 4/5F and 4/5R above was unsuccessful in our hands. However, we were able to amplify most of the desired region by synthesizing a primer falling at the 5Ј-end of the exon 4 coding sequence (designated 4/5Fa above) and using it with the original intronic reverse primer (4/5R above) falling 3Ј of exon 5. This yielded a PCR product that included the entire exon 5, the intron between exons 4 and 5, and all but 20 nucleotides of exon 4 (constituting Ͻ2% of the VDR-coding region).
Comparative genomic hybridization (CGH)
CGH is a recently developed technique capable of detecting large scale chromosomal gains and/or losses in tumors. Probe (tumor) DNA and normal reference DNA were labeled differentially with fluorescein 12-deoxyuridine 5-triphosphate and Texas Red 5-deoxyuridine 5-triphosphate, respectively. Equal amounts of each were suspended in hybridization mixture and competitively hybridized to normal human metaphase chromosomes. The chromosomes were counterstained with 4,6-diamino-2-phenylindole for their identification. The fluorescence intensities and staining pattern were visualized using a cooled chargecoupled device camera attached to a microscope and quantitated as previously described (20, 21) .
Results
Analysis of allelic loss at the VDR locus
Allelic loss was examined in 29 tumors from 14 patients who were heterozygous, or informative, for the TaqI RFLP found in VDR codon 352 (exon 9). Twenty-two of these tumors were analyzed for allelic loss by Southern blotting, and 7 were analyzed by PCR. No loss of heterozygosity (LOH) at this location directly within the VDR gene was found in any of the 29 informative tumors analyzed. Figure  1 shows two examples of patients heterozygous for the TaqI polymorphism, but with no tumor-specific LOH; one was analyzed by Southern blotting (Fig. 1a) , and the other by PCR (Fig. 1b) .
Sequence analysis of the VDR gene
The VDR gene's coding region and splice junctions were sequenced in all 59 tumor DNA samples, looking for subtle inactivating mutations. No mutations of the VDR gene were observed. The sequence analysis did identify a number of genetic polymorphisms. Twelve of 33 (36.4%) patients were heterozygous for a previously described ATG3 ACG start codon polymorphism at the beginning of exon 2 (22) (23) (24) . Eleven of 33 (33.3%) were homozygous for ACG, and the remaining 10 patients (30.3%) were homozygous for ATG. At the TaqI polymorphism in exon 9, codon 352, 16 of 33 (48%) patients were heterozygous for the TTGA3 TCGA polymorphism in complete concordance with our restriction enzyme analyses. There were 2 patients whose tumors were heterozygous by sequence but for whom LOH analysis could not be performed because the matched DNA from peripheral blood leukocytes was degraded and unsuitable for PCR amplification. In addition, several putative, single nucleotide polymorphisms, which were either intronic or silent mutations causing no change in the amino acid sequence, were found in sequencing the tumor DNA samples. At base 57 of exon 2 (codon 19), 1 patient (3%) was heterozygous for an AAC3 AAT polymorphism, previously undescribed to the best of our knowledge (both encode Asn). Two of 33 (6%) patients were heterozygous for a C3 T polymorphism at base 8 of the intron between exons 2 and 3, and 1 (3%) was homozygous for the variant T at this position. An additional intronic polymorphism was identified at base 75 between exons 7 and 8. Three patients (9%) were heterozygous for a 1-base, G, insertion at this position. Finally, at base 147 of exon 4 (codon 141), 1 patient (3%) was heterozygous for a TCC3 TCT polymorphism (both encode Cys). Representative confirmation of the ability of our sequencing methodology to sensitively detect heterozygous mutations is shown in Fig. 2 , which depicts the sequence of a tumor heterozygous for the polymorphism found at the start codon in exon 2.
Comparative genomic hybridization
CGH analysis of 37 uremia-associated parathyroid tumors showed no chromosomal losses in the region of the VDR gene (12cen-q12; data not shown) (25) . This is in agreement with our data, which showed no allelic loss by PCR and/or Southern blotting.
Discussion
Severe secondary or tertiary hyperparathyroidism is an important clinical challenge in the management of patients with chronic renal failure. Typically occurring in the setting of long term hemodialysis, increased autonomy in parathyroid function and decreased responsiveness to standard medical therapy with vitamin D analogs and calcium may cause hypercalcemia, bone pain, pruritus, fractures, muscle weakness, and soft tissue calcifications and may require treatment by surgical parathyroidectomy (26 -29) .
A majority of chronic renal failure patients with severe refractory hyperparathyroidism harbor at least one monoclonal parathyroid tumor (1, 2) , but the specific acquired genetic defects that confer the selective growth advantage implied by such clonality remain poorly understood. Defining these genetic mechanisms is pertinent because the clonal status of a tumor seems to be an important determinant of its clinical profile. Monoclonal growth could contribute to disease severity through critical enlargement of the parathyroid cell burden and/or an abnormal Ca 2ϩ -PTH set-point, both of which are seen in other types of monoclonal parathyroid tumors and are characteristics of refractory uremic hyperparathyroidism (10, 30 -36) . In fact, large parathyroid gland size has been associated with higher levels of PTH and more severe bone symptoms refractory to medical therapy with calcitriol (33) (34) (35) , a nodular parathyroid growth pattern with a higher proliferative rate (37) , and a significantly reduced density of both the VDR and the Ca 2ϩ -sensing receptor (38, 39) compared with generalized hyperplasia.
The VDR gene is a compelling candidate parathyroid tumor suppressor gene, because a parathyroid cell in which both VDR alleles become somatically inactivated would plausibly gain a selective growth advantage through impaired responsiveness to the antiproliferative influence of 1,25-dihydroxyvitamin D 3 (40 -42) . Furthermore, recurrent VDR gene defects would both explain the observation of abnormal VDR expression and testify to its pathogenetic significance in driving the growth of medically refractory uremia-associated parathyroid tumors.
Additional evidence for a possible role of the VDR gene comes from observations that have suggested a role of the VDR gene polymorphism in controlling parathyroid function and growth in patients with primary or secondary uremic hyperparathyroidism (43, 44) . However, this issue remains a matter of debate (45) .
Therefore, to assess VDR gene inactivation's potential role in the primary pathogenesis of refractory uremic hyperparathyroidism, we rigorously analyzed the VDR gene in 59 parathyroid tumors surgically resected from uremic patients. We used multiple methods that collectively were capable of finding both large (chromosomal and subchromosomal) scale and subtle DNA defects of the types that commonly contribute to inactivation of authentic tumor suppressors. Our observations indicate that such tumor-specific defects occur rarely if at all and make it unlikely that somatic mutation in the VDR gene plays an important role in triggering or driving clonal expansions in uremic parathyroid glands. Consistent with our results, Chudek et al. (46) found an extremely low frequency of LOH on 12q in a similar set of tumors (with such LOH excluding the VDR locus in one tumor); neither VDR mutation analysis nor CGH was performed in this study. Although our methods did not exclude some possible inactivating lesions, such as mutation of the VDR promoter or its hypermethylation, knowledge of established tumor suppressor genes makes it implausible that frequent clonal VDR inactivation would occur to the complete exclusion of generally common mechanisms such as coding region mutation and deletion. Decreased VDR expression might still be functionally significant in clonal uremic hyperparathyroidism, but at best would appear to be a downstream consequence, directly or indirectly, of more primary acquired genetic abnormalities or of other manifestations of the growth-disturbed cell. Thus, somatic changes in genes other than the VDR are probably responsible for the emergence of monoclonal parathyroid growth and for the development of a more severe clinical phenotype in uremiaassociated hyperparathyroidism.
